Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100098 | 0.91 | CCKBR (0.56) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL4105677 | 0.90 | CCKBR (0.58) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL3235912 | 0.87 | CCKBR (0.57) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL3241207 | 0.86 | CCKBR (0.57) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL3235835 | 0.86 | CCKBR (0.59) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL3224653 | 0.86 | CCKBR (0.53) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL3238742 | 0.85 | CCKBR (0.55) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL3225855 | 0.85 | CCKBR (0.55) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL3235841 | 0.85 | CCKBR (0.54) | CCKBRCHRM1MEN1LMNAALB | |
| SCHEMBL3229900 | 0.85 | CCKBR (0.61) | CCKBRCHRM1MEN1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | claimed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | CCKBR 1128/4885CHRM1 1396/4885MEN1 4607/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | CCKBR 1128/4885CHRM1 1396/4885MEN1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.